SCHEMBL20579798

SCHEMBL20579798

O=C(OCC(F)(F)F)c1c(-c2ccc3c(c2)OCO3)nc2ccccn12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 9/20 0.51
▸ L3MBTL1 Q9Y468 2/20 0.51
▸ LMNA P02545 1/20 0.51
▸ HTT P42858 1/20 0.51
▸ CYP1A2 P05177 2/20 0.50
▸ CYP2C9 P11712 2/20 0.50
▸ CYP2C19 P33261 2/20 0.50
▸ ALDH1A1 P00352 11/20 0.48
▸ KDM4E B2RXH2 9/20 0.48
▸ GAA P10253 8/20 0.48
▸ MAPT P10636 8/20 0.48
▸ HPGD P15428 4/20 0.48
▸ MAPK1 P28482 3/20 0.48
▸ NPSR1 Q6W5P4 2/20 0.48
▸ TSHR P16473 1/20 0.48
▸ HSD17B10 Q99714 1/20 0.48
▸ CYP3A4 P08684 1/20 0.46
▸ CYP2D6 P10635 1/20 0.46
▸ RAB9A P51151 5/20 0.46
▸ NPC1 O15118 4/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20579959 0.87 SMN1; SMN2 (0.67) SMN1; SMN2L3MBTL1LMNAHTTCYP1A2
SCHEMBL20579758 0.82 CYP1A2 (0.72) SMN1; SMN2CYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL20579783 0.81 CYP1A2 (0.60) SMN1; SMN2HTTCYP1A2CYP2C9CYP2C19
SCHEMBL20579832 0.81 CYP1A2 (0.66) SMN1; SMN2HTTCYP1A2CYP2C9CYP2C19
SCHEMBL20579820 0.80 CYP1A2 (0.62) SMN1; SMN2CYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL21097067 0.79 SMN1; SMN2 (0.60) SMN1; SMN2CYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL20579799 0.79 SMN1; SMN2 (0.60) SMN1; SMN2L3MBTL1LMNAHTTCYP1A2
SCHEMBL20580270 0.77 SMN1; SMN2 (0.55) SMN1; SMN2CYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL20580266 0.74 CYP1A2 (0.57) SMN1; SMN2CYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL20579760 0.73 MAPK1 (0.74) SMN1; SMN2LMNAHTTCYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10323033-B2 Imidazo[1,2-A]pyridine-3-carboxylate derivative and preparation method thereof KNU-INDUSTRY COOPERATION FOUNDATION (KR) 2019-06-18 — — US disclosed
US-10323033-B2 Imidazo[1,2-A]pyridine-3-carboxylate derivative and preparation method thereof KNU-INDUSTRY COOPERATION FOUNDATION (KR) 2019-06-18 — — US disclosed
US-20180354948-A1 IMIDAZO[1,2-A]PYRIDINE-3-CARBOXYLATE DERIVATIVE AND PREPARATION METHOD THEREOF KNU-INDUSTRY COOPERATION FOUNDATION (KR) 2018-12-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180354948-A1 IMIDAZO[1,2-A]PYRIDINE-3-CARBOXYLATE DERIVATIVE AND PREPARATION METHOD THEREOF AZI2, AOC3, AOC2 SMN1; SMN2 1569/4885L3MBTL1 4290/4885LMNA 3584/4885
US-10323033-B2 Imidazo[1,2-A]pyridine-3-carboxylate derivative and preparation method thereof AZI2, AOC3, AOC2 SMN1; SMN2 1569/4885L3MBTL1 4290/4885LMNA 3584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback